Mirogabalin is primarily used in the treatment of neuropathic pain, particularly in conditions such as diabetic peripheral neuropathy and postherpetic neuralgia. It works by selectively binding to the α2δ subunit of voltage-gated calcium channels in the central nervous system, which helps reduce the release of neurotransmitters involved in pain signaling. This mechanism provides effective pain relief for patients suffering from chronic pain conditions. Additionally, mirogabalin has shown potential in managing fibromyalgia and other central sensitization disorders due to its ability to modulate pain pathways. Its favorable safety profile and lower risk of drug interactions make it a suitable option for long-term pain management in diverse patient populations.